MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03978ntm a2200313 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12102116 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20220404103831.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150118s2022 ua a f bm 000 0 eng | |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-EULC |
| Transcribing agency |
EG-EULC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| Item number |
M.S.T |
| Edition number |
22 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Abdulazeem, Muhammad Muneeb Muhammad, |
| 9 (RLIN) |
33917 |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Targeting brain insulin signaling pathway for modulation of cognitive impairment in a rat model of type II diabetes mellitus / |
| Statement of responsibility, etc |
By Muhammad Muneeb Muhammad Abdulazeem, (Bachelor degree of Pharmacy (2015), Teaching Assistant, Pharmacology, Toxicology & Biochemistry Department, Faculty of Pharmacy, Future University in Egypt (FUE)); Supervision of Dr. Samira Saleh Mostafa,(Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Dr. Suzan Mohamed Mansour, Associate Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Future University in Egypt, Dr. Reham Atef Muhamed, Faculty of Pharmacy, Cairo University). |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
إستهداف مسار إشارة الأنسولين بالمخ لتطبيع ضعف الإدراك في نموذج الجرذ المصاب بالسكري من النوع الثاني |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xii, 194 pages, 6 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
22 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Supervision of Dr. Samira Saleh Mostafa,(Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Dr. Suzan Mohamed Mansour, Associate Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Future University in Egypt, Dr. Reham Atef Muhamed, Faculty of Pharmacy, Cairo University) |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Cairo University, Faculty of pharmacy, Department of Pharmacology & Toxicology, 2022. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc |
The study aimed to explore the possible neuroprotective effects of VitD and/or RSV in T2DM-induced cognitive deficits. It investigates the crosstalk between insulin/AKT/GSK-3β and the canonical/non-canonical Wnt/β-catenin signaling in the hippocampus.<br/>T2DM was induced by a fat sucrose diet and a single dose of streptozotocin (STZ). Diabetic rats were randomly allocated into 4 groups, a diabetic control and three groups treated for 5 weeks with RSV (15 mg/kg/day, PO), VitD (cholecalciferol, 500 IU/kg/day, PO) or their combination. A normal-control group was run concomitantly. We determined antineuropathic effects (cognitive function and histopathological examination), metabolic abnormalities (glucose, insulin, HOMA-IR, FFA and lipid profile), neuro-inflammation (IL-23, IL-27), Wnt/β-catenin signaling, canonical (ApoE-4, Wnt5a, pS9 GSK-3β, pS675 β-catenin, pS37 β-catenin) and non-canonical (RhoA, Rac1, p-Akt ), blood brain barrier integrity markers (Annexin A1, claudin 3 and VE-cadherin), dementia hallmarks (p-Tau and Aβ protein), and gene expression of insulin and α7nACh receptors.<br/>Treatment with VitD and/or RSV significantly hampered T2DM-induced disturbances in metabolic profile and stimulated both canonical/noncanonical Wnt/β-catenin cassettes in the hippocampus with activation of their downstream molecules. They hindered hippocampal ApoE-4 content, Tau hyperphosphorylation and Aβ deposition. The amended pathways were reflected as improved performance in Morris water maze and novel object recognition tests besides restored histological architecture.<br/>The current study provides evidence for expanding the use of VitD and RSV against T2DM-induced cognitive and memory impairment. The study also suggests a superior benefit of combining both treatments over either drug alone |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstracts in English and Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacology |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
DSpace electronic resources |
| Uniform Resource Identifier |
<a href="http://repository.fue.edu.eg/xmlui/handle/123456789/5779">http://repository.fue.edu.eg/xmlui/handle/123456789/5779</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Thesis |
| Source of classification or shelving scheme |
Dewey Decimal Classification |